DRW Securities’s Cue Biopharma CUE Stock Holding History

DRW Securities’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-763	Closed	-$108K	–	83
2018 Q4	$108K	Buy	763 +96	+14%	+$17.4K	0.01%	60
2018 Q3	$181K	Buy	+667	New	+$193K	0.01%	42

Other funds holding CUE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

DRW Securities's CUE Position: Q1 2019 in Review

DRW Securities sold out of Cue Biopharma (CUE) in Q1 2019, closing a stake of 763 shares — an estimated $108K sold.

DRW Securities first reported a position in CUE in Q3 2018 and held it in 2 quarters. The position peaked at $181K in Q3 2018. 38 funds tracked by Wall St. Rank hold CUE as of Q1 2019.

DRW Securities reported no remaining Cue Biopharma position as of Q1 2019 after selling out during the quarter.
DRW Securities sold 763 Cue Biopharma shares in Q1 2019, an estimated $108K.
DRW Securities first reported a position in Cue Biopharma in Q3 2018 and held it in 2 quarters.
DRW Securities's Cue Biopharma position peaked at $181K in Q3 2018.
38 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2019.

Based on DRW Securities's 13F filing for Q1 2019, filed 15 May 2019.